Conference Coverage

VIDEO: Old, reliable drugs cut heart failure readmissions


 

At ACC 14

WASHINGTON, D.C. – Heart failure patients discharged on inexpensive, guideline-recommended drugs were half as likely to be readmitted for the condition within* 30 days, compared with those who weren’t given the drugs, according to a study of the Alabama Heart Failure Project that used Medicare data.

Dr. Kumar Sanam, an advanced heart failure fellow at the University of Alabama, Birmingham, presented the study at the annual meeting of the American College of Cardiology, and sat down with us to discuss the take-home implications of the study.

emechcatie@frontlinemedcom.com

*CORRECTION, 4/22/2014: An earlier version of this story misstated the follow-up period.

Recommended Reading

CoreValve holds size advantage for U.S. TAVR
MDedge Internal Medicine
Latest heart failure guidelines break new ground
MDedge Internal Medicine
FDA to probe saxagliptin’s heart failure risk
MDedge Internal Medicine
Mini-VADs could transform heart failure therapy
MDedge Internal Medicine
Myocardial fibrosis assessment fine-tunes ICD selection
MDedge Internal Medicine
PITCH is called for a balk
MDedge Internal Medicine
Medicare to cover cardiac rehab for some HF patients
MDedge Internal Medicine
HFPEF’s diverse features pose management and trial challenges
MDedge Internal Medicine
Physician/patient communication on ICDs deemed problematic
MDedge Internal Medicine
Survival after TAVR superior to surgery in high-risk aortic stenosis patients
MDedge Internal Medicine